Certara, Inc. (NASDAQ:CERT) Sees Large Drop in Short Interest

Certara, Inc. (NASDAQ:CERT) was the target of a significant drop in short interest during the month of September. As of September 30th, there was short interest totalling 3,920,000 shares, a drop of 9.5% from the September 15th total of 4,330,000 shares. Approximately 3.5% of the shares of the stock are sold short. Based on an average trading volume of 1,110,000 shares, the days-to-cover ratio is presently 3.5 days.

Certara Trading Up 3.1 %

CERT traded up $0.35 during trading on Thursday, reaching $11.57. 1,956,478 shares of the stock traded hands, compared to its average volume of 754,031. The company has a quick ratio of 2.61, a current ratio of 2.61 and a debt-to-equity ratio of 0.28. The stock’s 50-day moving average is $11.67 and its 200 day moving average is $14.48. Certara has a 12 month low of $10.35 and a 12 month high of $19.87. The stock has a market capitalization of $1.86 billion, a PE ratio of -28.77, a P/E/G ratio of 5.40 and a beta of 1.49.

Certara (NASDAQ:CERT) last announced its earnings results on Tuesday, August 6th. The company reported $0.07 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.03). The business had revenue of $93.31 million for the quarter, compared to the consensus estimate of $96.01 million. Certara had a negative net margin of 21.64% and a positive return on equity of 3.03%. The firm’s revenue for the quarter was up 3.2% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.10 EPS. Equities analysts anticipate that Certara will post 0.27 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts have recently commented on CERT shares. Barclays cut their price target on Certara from $16.00 to $14.00 and set an “equal weight” rating on the stock in a research note on Tuesday. UBS Group upgraded shares of Certara from a “neutral” rating to a “buy” rating and set a $16.00 price target for the company in a research report on Friday, September 27th. JMP Securities reiterated a “market perform” rating on shares of Certara in a report on Wednesday, July 10th. KeyCorp decreased their price objective on Certara from $23.00 to $20.00 and set an “overweight” rating for the company in a report on Thursday, July 11th. Finally, Robert W. Baird reduced their price target on Certara from $19.00 to $18.00 and set a “neutral” rating on the stock in a research report on Wednesday, August 7th. Six investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to data from MarketBeat, Certara has an average rating of “Hold” and a consensus target price of $17.08.

Insider Activity at Certara

In other news, insider Patrick F. Smith sold 5,409 shares of the business’s stock in a transaction on Monday, October 7th. The stock was sold at an average price of $11.03, for a total transaction of $59,661.27. Following the completion of the transaction, the insider now owns 50,091 shares of the company’s stock, valued at approximately $552,503.73. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, insider Patrick F. Smith sold 5,409 shares of the company’s stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $11.03, for a total transaction of $59,661.27. Following the completion of the transaction, the insider now directly owns 50,091 shares in the company, valued at $552,503.73. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Leif E. Pedersen sold 51,224 shares of the stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $11.29, for a total transaction of $578,318.96. Following the completion of the transaction, the insider now directly owns 99,704 shares of the company’s stock, valued at approximately $1,125,658.16. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. 2.39% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of CERT. Sei Investments Co. increased its stake in Certara by 12.4% in the first quarter. Sei Investments Co. now owns 715,514 shares of the company’s stock valued at $12,793,000 after purchasing an additional 79,013 shares in the last quarter. Geneva Capital Management LLC raised its stake in Certara by 15.1% during the 1st quarter. Geneva Capital Management LLC now owns 4,404,199 shares of the company’s stock worth $78,747,000 after buying an additional 579,349 shares during the period. Wasatch Advisors LP boosted its holdings in Certara by 23.4% in the first quarter. Wasatch Advisors LP now owns 4,924,845 shares of the company’s stock worth $88,056,000 after acquiring an additional 932,598 shares in the last quarter. Motley Fool Asset Management LLC grew its stake in Certara by 94.0% in the first quarter. Motley Fool Asset Management LLC now owns 96,792 shares of the company’s stock valued at $1,731,000 after acquiring an additional 46,897 shares during the period. Finally, Silvercrest Asset Management Group LLC increased its holdings in shares of Certara by 27.3% during the first quarter. Silvercrest Asset Management Group LLC now owns 516,300 shares of the company’s stock valued at $9,231,000 after acquiring an additional 110,636 shares in the last quarter. Institutional investors and hedge funds own 73.96% of the company’s stock.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.